Nation and world news briefs
1 in 3 Americans would refuse COVID-19 vaccine, new Gallup poll findsOne in 3 Americans would refuse an FDA-approved coronavirus vaccine even if it were offered at no cost, a new Gallup poll released Friday found.The results, based on survey conducted between July 20 and Aug. 2, found that 65% of respondents said they would accept the offer and get themselves vaccinated while 35% said they would not.The new poll falls in line with previous Gallup findings suggesting political party preference plays a strong role in Americans’ views on COVID-19.Eighty-one% of Democrats would be willing to get v...
Tribune News Service
In search for COVID-19 treatments, consumer group pushes drugmaker Gilead to test alternative to remdesivir
The pharmaceutical company that makes remdesivir — the only medication that has emergency authorization to fight COVID-19 — should also be conducting human trials on a related drug with strong potential, according to a citizen advocacy group that believes the alternative could be more effective, less expensive and easier to produce.Washington, D.C.-based Public Citizen sent a letter dated Tuesday to the CEO of Gilead Sciences and top federal regulators, urging the company and the government to work together to move forward with clinical trials of the drug “or publicly provide evidence why it i...
Study: Antiviral drug remdesivir helps white, Black and Latino patients equally
CHICAGO — Remdesivir, the only drug given emergency approval for treatment of COVID-19, appears to provide equal benefits to white, Asian, Black and Latino patients, according to an analysis led by researchers at University of Chicago Medicine.It’s encouraging news, infectious disease experts say, because of the disparate effects of the disease on different groups. Black people are dying at higher rates than people of other races, and Latinos are contracting the disease at higher rates than others.Dr. Kathleen Mullane, a UChicago Medicine infectious disease expert, said the results — which wer...
Hydroxychloroquine is the most disappointing, disavowed drug that researchers keep studying for COVID-19
Barely three months ago, the anti-malarial drug that President Donald Trump touted seemed like such a sure bet against COVID-19 that Susanna Naggie had a tough time setting up a national clinical trial comparing it to placebo. Colleagues said giving a fake pill would be unethical since the real thing might save lives.Now, hydroxychloroquine, or HCQ, has fallen into such disfavor that healthcare workers are leery of Naggie’s trial. Called HERO (a loose acronym for HEalth Care Worker pROphylaxis Against COVID-19) it is designed to see if the drug can protect them from infection.“Our original rec...
The Philadelphia Inquirer
Moderna delays Phase 3 trial for COVID-19 vaccine
Moderna’s heavily anticipated trial for a coronavirus vaccine, which was set to begin next week, has been delayed.“Moderna has previously disclosed that the Phase 3 trial of its COVID-19 vaccine candidate mRNA-1273 is expected to begin in July. The trial is still expected to begin in July and we expect to be the first to start a Phase 3 trial,” read a company statement sent to The New York Daily News Thursday. “We have worked closely with NIH/OWS to align on the final protocol in order to begin the trial on time.”The Phase 3 study, which includes 30,000 patients, was initially supposed to begi...
New York Daily News
Small turnout expected this week as St. Louis Blues begin Phase 2 workouts
ST. LOUIS — For the first time in more than three months, St. Louis Blues players will be on the ice at Centene Community Ice Center as the team formally begins Phase 2 of the NHL’s return-to-play plan Monday. Phase 2 consists of small-group individual workouts, and in the case of the Blues — the emphasis is on the “small.”General manager Doug Armstrong said only three players are scheduled to skate at Centene this week. Since the Phase 2 program is voluntary, Armstrong declined to mention their names.As for the rest of the squad, Armstrong said: “Most of our guys are skating with bigger group...
St. Louis Post-Dispatch
Commentary: On a doctor's right to try in the age of COVID-19
Should doctors who are working in COVID-19 intensive care units have access for themselves to Moderna’s potential coronavirus vaccine? U.S. health care workers are infected with the virus every day. If we have a probable vaccine that is almost certainly reasonably safe and likely to be effective, why shouldn’t doctors — who are scientifically trained to make these judgments — be allowed to vaccinate themselves to protect both their own lives and those they treat?Yes, it’s possible that there will be unacceptable side effects. Like other medicines, a COVID-19 vaccine may be right for some peopl...
Tribune News Service
Pregnant women rarely are in medical studies. Penn wants moms-to-be in coronavirus trials.
PHILADELPHIA — The University of Pennsylvania has opened two studies of convalescent plasma for COVID-19 to a group that is almost always excluded from clinical trials: pregnant women.The medical community has been lobbying in recent years to include pregnant and breast-feeding women in clinical research, and the coronavirus pandemic has heightened the need. In March, for example, the Coalition to Advance Maternal Therapeutics — made up of 20 medical and advocacy groups — wrote to leaders of the National Institutes of Health and the U.S. Food and Drug Administration to urge inclusion of such w...
The Philadelphia Inquirer
Anti-malaria drug hydroxychloroquine does little to prevent COVID-19, trial finds
An anti-malaria drug that has been trumpeted as a therapy for COVID-19 was unable in a University of Minnesota clinical trial to prevent the onset of the infectious disease.The results of the nation’s first randomized trial with the drug, hydroxychloroquine, against COVID-19 will disappoint doctors who had hoped for new therapies against the pandemic. Many prescribers had given it off-label to COVID-19 patients — in the absence of other options — and President Donald Trump had been an early champion of the drug and disclosed in mid-May that he was taking it for the preventive benefit that the ...
Star Tribune (Minneapolis)
Study: Older adults underrepresented in cholesterol drug trials
A recent study shows that the people most likely to be affected by heart disease — older adults and women — are the least represented in randomized clinical trials for cholesterol-lowering medications.Older adults are more likely than young adults to have heart and vascular disease while the leading cause of death in women is heart disease, according to a press release from Johns Hopkins Medicine.But in an analysis of the trends in the types of 485,409 people enrolled in 60 studies from 1990 to 2018, researchers at Johns Hopkins Medicine found that despite some progress, older adults and women...
The Atlanta Journal-Constitution